- Patients who completed the 13-week treatment of painful diabetic peripheral
neuropathy in Study A0081163.
- Patients must be able to understand and cooperate with study procedures and have
signed a written informed consent prior to entering the study
- Patients who experienced serious adverse events in the preceding study (A0081163)
that were determined by the investigator or the study sponsor to be causally related
to the study medication.
- Patients exhibiting treatment non-compliance in the preceding study (A0081163)